Company profile: Abac Therapeutics
1.1 - Company Overview
Company description
- Provider of precision antimicrobial drug discovery and development, creating first-in-class, pathogen-specific antibiotics for MDR Gram-negative infections. Offers the PasNas scalable, multiplexed platform to identify high-quality leads across compounds and bacterial species, and advances agents with suitable pharmacokinetics/toxicology, leveraging public-private collaborations to combat antimicrobial resistance.
Products and services
- Precision Antimicrobial Agents: ABAC engineers pathogen-specific antibiotics for severe MDR Gram-negative infections, minimizing microbiome impact and reducing resistance while integrating suitable pharmacokinetics and toxicological characteristics
- Drug Discovery and Development for AMR: ABAC develops first-in-class antibiotics leveraging innovative approaches and precision medicine, embedding early suitable pharmacokinetics and toxicological characteristics to combat antimicrobial resistance
- PasNas Technology Platform: ABAC builds a scalable platform to identify high-quality antibiotic leads, adaptable across various chemical compounds and diverse bacterial species
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Abac Therapeutics
Aptorum
HQ: United Kingdom
Website
- Description: Provider of pharmaceutical discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, with a focus on infectious diseases and cancers, including orphan oncology indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptorum company profile →
Generate:Biomedicines
HQ: United States
Website
- Description: Provider of a machine learning-powered platform to create new drugs on demand across biologic modalities, accelerating therapeutic identification and validation; Chroma, an open-source AI model that programs novel proteins with targeted properties; and a clinical pipeline (GB-0895 for asthma, GB-0669 targeting SARS-CoV-2), with an expanded collaboration with Amgen to develop novel proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generate:Biomedicines company profile →
Enanta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule anti-infective drug R&D, discovering and developing therapies including MAVYRET (glecaprevir/pibrentasvir), a hepatitis C virus protease inhibitor regimen requiring only eight weeks of treatment; EDP-514, a novel hepatitis B core inhibitor; zelicapavir (EDP-938), an RSV N-protein inhibitor in Phase 2 for pediatric and adult patients; EDP-323, an RSV L-protein inhibitor; and EDP-235, a 3CL protease inhibitor for COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enanta Pharmaceuticals company profile →
Spero Therapeutics
HQ: United States
Website
- Description: Provider of oral and IV antibiotic therapies for gram-negative infections: Tebipenem HBr for complicated urinary tract infections and acute pyelonephritis to reduce hospitalizations and support transition from IV to home care; SPR720, an oral investigational agent for nontuberculous mycobacterial pulmonary disease; and SPR206, an IV candidate for multidrug-resistant Gram-negative infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spero Therapeutics company profile →
Paratek Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies based on novel tetracycline chemistry, including NUZYRA, an FDA-approved tetracycline-class antibiotic for adults with CABP and ABSSSI caused by select susceptible microorganisms, and SEYSARA, an FDA-approved oral therapy for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paratek Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Abac Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Abac Therapeutics
2.2 - Growth funds investing in similar companies to Abac Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Abac Therapeutics
4.2 - Public trading comparable groups for Abac Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →